Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03041311 · ClinicalTrials.gov registry record · Phase 2
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
A Phase 2 study of Small-cell Lung Cancer, sponsored by G1 Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 20
- Study locations
NCT03041311 is a Phase 2 study of Small-cell Lung Cancer that has completed, run by G1 Therapeutics. The registered enrollment target is 107 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03041311, a Phase 2 study of Small-cell Lung Cancer, has completed, sponsored by G1 Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study was a randomized, double-blinded, placebo-controlled design. Approximately, 100 patients were randomized to trilaciclib + E/P/A or placebo + E/P/A in the study.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Atezolizumab
- DRUG Etoposide
- DRUG Trilaciclib
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- St. Jude Heritage Healthcare - Fullerton
- Loma Linda University - Loma Linda
- UCLA Medical Center - Santa Monica Hematology And Oncology - Santa Monica
- Redwood Regional Medical Group (RRMG) - Fountain Grove - Santa Rosa
- Singing River Health System - Whittier
Georgia
- Piedmont Cancer Institute - Atlanta
- Northside Hospital - Georgia Cancer Specialists - Atlanta
Missouri
- St. Louis Cancer Care, LLP, North County - Bridgeton
- The Alvin J. Siteman Cancer Center - Center for Advanced Med - St Louis
Texas
- Valley Cancer Associates - Harlingen
- Millennium Oncology - Houston
Illinois
- Joliet Oncology-Hematology Associates - Joliet
Indiana
- Horizon Oncology Center - Lafayette
Louisiana
- Ochsner Clinic Foundation - New Orleans
New Jersey
- Summit Medical Group, P.A. - Morristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2020-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03041311
The ClinicalTrials.gov registry entry for NCT03041311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (54% lower). The listed sponsor is G1 Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03041311 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, Missouri.
Frequently Asked Questions
What is clinical trial NCT03041311 about?
NCT03041311 is a clinical study titled "Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC". This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly ...
What is the current status of trial NCT03041311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2017-06-29. Estimated completion is 2020-10-29.
What conditions does trial NCT03041311 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT03041311?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), Trilaciclib (DRUG).
Who is sponsoring clinical trial NCT03041311?
This trial is sponsored by G1 Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03041311 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.